Trung Huynh
Stock Analyst at UBS
(1.86)
# 1087
Out of 5,327 analysts
37
Total ratings
56.52%
Success rate
23.34%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb | Maintains: Neutral | 60 54 | 48 | 12.5% | 5 | Apr 11, 2025 | |
PFE Pfizer | Maintains: Neutral | 28 24 | 22.95 | 4.58% | 5 | Apr 8, 2025 | |
CABA Cabaletta Bio | Maintains: Buy | 10 7 | 1.27 | 451.18% | 2 | Apr 1, 2025 | |
INSM Insmed | Maintains: Strong Buy | 105 110 | 69.33 | 58.66% | 4 | Mar 6, 2025 | |
JSPR Jasper Therapeutics | Initiates Coverage On: Buy | 38 | 4.71 | 706.79% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 44 | 20.85 | 111.03% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 1130 738 | 603.5 | 22.29% | 1 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 13 | 2.04 | 537.25% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Strong Buy | 612 710 | 869.51 | -18.34% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 170 175 | 154.93 | 12.95% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 220 200 | 280.87 | -28.79% | 3 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 125 126 | 83.33 | 51.21% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 170 | 191.17 | -11.07% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Mar 23, 2021 |